Novavax Inc. started a large late-stage study of the company’s experimental Covid-19 vaccine in the United States after delaying the trial twice due to issues in scaling up the manufacturing process.

Vaccine maker Novavax Inc. pushed back the start of a U.S.-based, late-stage trial for the company’s experimental Covid-19 vaccine.

Despite the constant need for social distancing, mask-wearing and the isolation and economic uncertainty that resulted from the Covid-19 outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.

Novavax Inc. is on track to begin a delayed U.S.-based, late-stage study of the company’s experimental coronavirus vaccine during November

Leading pharmaceutical companies – including Moderna, Pfizer and AstraZeneca – are racing ahead to develop and distribute a Covid-19 vaccine.

French drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their Covid-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.